Search

Displaying results 111 - 120 of 10000 in total
  1. Drug

    TN-201

    go.drugbank.com/drugs/DB18700
    Investigational

    TN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.

    Synonyms: Native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene
  2. Drug

    Nendratareotide uzatansine

    go.drugbank.com/drugs/DB18351
    Investigational

    Nendratareotide uzatansine is a peptide-drug conjugate comprising a peptide analog of somatostatin conjugated to the cytotoxin mertansine.

    Synonyms: Peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine
  3. Drug

    Veverimer

    go.drugbank.com/drugs/DB18977
    Investigational

    Veverimer is under investigation in clinical trial NCT03390842 (Long-term Safety Extension to Study TRCA-301).

    Synonyms: N1,n3-bis(prop-2-en-1-yl)propan-1,3-diamine copolymer with 1,2-dichloroethane and prop-2-en-1-amine, 1,3-propanediamine, n1,n3-di-2-propen-1-yl-, polymer with 1,2-dichloroethane and 2-propen-1-amine
  4. Drug

    TN-401

    go.drugbank.com/drugs/DB18140
    Investigational

    TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.

    Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene
  5. Drug

    Anbenitamab

    go.drugbank.com/drugs/DB18411
    Investigational

    Synonyms: FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4, IMMUNOGLOBULIN G1 (369-SERINE,371-ALANINE,408-LYSINE,410-VALINE), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2 DOMAIN IV)(HUMAN-MUS MUSCULUS MONOCLONAL RHUMAB 4D5 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS
  6. Drug

    DT-DEC01

    go.drugbank.com/drugs/DB19433
    Experimental

    DT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.

    Synonyms: Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor
  7. Drug

    Eltrapuldencel-T

    go.drugbank.com/drugs/DB17329
    Investigational

    Synonyms: Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF)
  8. Drug

    Viagenpumatucel-L

    go.drugbank.com/drugs/DB16348
    Investigational

    Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).

    Synonyms: Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine
  9. Drug

    TRK-001

    go.drugbank.com/drugs/DB18577
    Investigational

    TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.

    Synonyms: Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta
  10. Drug

    CLL1-CD33 compound chimeric antigen receptor T cells

    go.drugbank.com/drugs/DB18568
    Investigational

    Synonyms: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33